Copyright
©The Author(s) 2017.
World J Hepatol. Aug 18, 2017; 9(23): 1001-1007
Published online Aug 18, 2017. doi: 10.4254/wjh.v9.i23.1001
Published online Aug 18, 2017. doi: 10.4254/wjh.v9.i23.1001
Table 4 MicroRNAs levels among the studied groups
| Variable(s) | Group I | Group II | Group III | P | P1 | P2 | P3 |
| HCC group (n = 57) | Cirrhotic group (n = 57) | Control group (n = 57) | |||||
| Median (range) | Median (range) | Median (range) | |||||
| MicroRNA 23a | 214 (21-218) | 211 (21-218) | 26 (20-219) | < 0.0001 | < 0.05 | < 0.001 | < 0.001 |
| MicroRNA 34 | 214 (22-220) | 211 (24-218) | 25 (20-219) | < 0.0001 | > 0.05 | < 0.001 | < 0.001 |
| MicroRNA 203 | 26 (21-219) | 26 (20-219) | 214 (21-225) | < 0.0001 | > 0.05 | < 0.001 | < 0.001 |
| MicroRNA 338 | 26 (21-219) | 26 (21-219) | 212 (29-217) | < 0.0001 | > 0.05 | < 0.001 | < 0.001 |
| MicroRNA 16 | 214 (21-225) | 213 (24-218) | 25 (20-219) | < 0.0001 | > 0.05 | < 0.001 | < 0.001 |
- Citation: Mohamed AA, Ali-Eldin ZA, Elbedewy TA, El-Serafy M, Ali-Eldin FA, AbdelAziz H. MicroRNAs and clinical implications in hepatocellular carcinoma. World J Hepatol 2017; 9(23): 1001-1007
- URL: https://www.wjgnet.com/1948-5182/full/v9/i23/1001.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i23.1001